Clinical Trials: Page
-
J&J reports positive results for HIV regimen
Patients taking a once-daily tablet comprised of darunavir and a regimen of Gilead drugs demonstrated low virologic rebound rates and high virologic suppression.
By Jacob Bell • July 25, 2017 -
Genocea readies Phase 3 for herpes drug
Genocea's Phase 2b immunotherapy data could be a shot in the arm for treatment of recurrent genital herpes.
By Suzanne Elvidge • July 25, 2017 -
Explore the Trendline➔
Yelena Shander via Getty Images
TrendlineVaccine development
Vaccine developers are investing in shots for RSV, influenza and pneumococcal disease in a newly uncertain regulatory climate.
By BioPharma Dive staff -
Courtesy of Eli Lilly
Lilly maps out new approach to cancer R&D
Setting a new bar for its research efforts, the Indianapolis drugmaker will seek to out-license six assets while funneling R&D dollars toward priority projects.
By Ned Pagliarulo • July 25, 2017 -
Montgomery County Planning Commission
Keytruda failure another setback for PD-1/L1 class
Merck's flagship immunotherapy didn't significantly improve overall survival for some head and neck cancer patients — adding to a string of recent setbacks for the anti-PD-1 class.
By Jacob Bell • July 25, 2017 -
Gilead's combo shows no resistance in HIV
As hepatitis C revenues fall, Gilead is leaning on its HIV franchise, which has been showing strong data.
By Suzanne Elvidge • July 25, 2017 -
Bayer misses in mid-stage mesothelioma trial
The drug failed in a Phase 2 study as a treatment for patients with asbestos-linked cancer. Development will continue for other tumor types, however.
By Suzanne Elvidge • July 24, 2017 -
Nektar secures $400M deal with Lilly for Phase 1 drug
Lilly liked what it saw in the immunological candidate, paying $150 million upfront to gain access to a compound Nektar discovered just over a year ago.
By Ned Pagliarulo • July 24, 2017 -
Prescribed Reading: Bolt-on deals for Sanofi
The big pharma tries to fill its pipeline, Vertex touts strong CF data and the FDA gives three approvals.
By Lisa LaMotta • July 21, 2017 -
Ironwood touts positive data, but investors aren't sold
The company intends to move the 1,500 mg dose of IW-3718 into Phase 3 after lower doses missed primary outcome measures.
By Jacob Bell • July 20, 2017 -
Neurotrope stock tumbles again on Alzheimer's data
Sea-derived bryostatin-1 still isn't quite hitting the spot for Neurotrope in Alzheimer's disease.
By Suzanne Elvidge • July 20, 2017 -
Positive triple combo data sets up Vertex for big growth
The new data on its cystic fibrosis treatments lifted shares more than 20%, adding billions to the company's market capitalization.
By Jacob Bell • July 19, 2017 -
Abeona set to fly into Phase 3 after FDA chat
Following FDA guidance, Abeona is scooting EB-101 straight into Phase 3 for "butterfly disease."
By Suzanne Elvidge • July 19, 2017 -
Elizabeth Regan/BioPharma Dive
CymaBay touts positive seladelpar liver results
Results from a lower dose study showed efficacy without the liver toxicity issues, driving up shares of the stock.
By Suzanne Elvidge • July 18, 2017 -
New data from Alzheon shows long-term benefit for Alzheimer's
APOE4 homozygotes who received higher doses of Alzheon's candidate over multiple years had "sustained cognitive and functional benefits."
By Jacob Bell • July 17, 2017 -
Deep Dive
What do we know about the amyloid theory for Alzheimer's?
A growing knowledge of the science behind the disease is allowing researchers to better test potential therapies.
By Jacob Bell • July 17, 2017 -
Deep Dive
5 trends shaping Alzheimer's drug development
Almost all Alzheimer’s drugs have failed. But pharma continues to invest millions in hopes of finding a hit, motivated by market opportunity and armed with lessons learned.
By Ned Pagliarulo • July 17, 2017 -
Genentech BD: Alzheimer's continues to be a priority
Genentech's Tom Zioncheck sat down with BioPharma Dive to talk about the big biotech's work in Alzheimer's disease.
By Lisa LaMotta • July 17, 2017 -
Deep Dive
Alzheimer's drug developers still hoping for a homer
The unmet need presented by the ever-growing patient population coupled with better science has the Alzheimer's disease pipeline filling up.
By Malorye Allison Branca • July 17, 2017 -
Prescribed Reading: Rumors, blood and history in the making
Rumors swirl about a new CEO at Teva, hemophilia drugs are getting exciting and the first CAR-T therapy could be coming.
By Lisa LaMotta • July 14, 2017 -
VBI Vaccines takes a shot at HBV Phase 3
Third-generation vaccines could have a stab at the harder-to-protect older population.
By Suzanne Elvidge • July 13, 2017 -
FDA panel unanimously backs approval of Novartis CAR-T
If approved later this year for an aggressive type of leukemia, Novatis' tisagenlecleucel would be the first CAR-T therapy OK'd for commercial use.
By Ned Pagliarulo • July 12, 2017 -
FDA
Woodcock: We need better biomarkers
The CDER director says precision medicine has come a long way, but biomarkers will bring the advances even further.
By Lisa LaMotta • July 12, 2017 -
Kadmon ROCKing some positive results
The biotech's ROCK2 inhibitor cut steroid use post-transplant for two-thirds of patients.
By Suzanne Elvidge • July 12, 2017 -
BioMarin, Spark, raising the stakes for hemophilia
The hemophilia market heats up as exciting technology, including gene therapy and RNA interference, are changing the the disease landscape.
By Lisa LaMotta • July 12, 2017 -
Sponsored by PPD Laboratories
There's an app for that: Busy investigators can now manage clinical trials on the go
Tapping into a ubiquitous trend among businesses, one major CRO lab is developing an app to communicate more efficiently with its clients, investigators and clinical trial managers.
By Roni Robbins • July 11, 2017
Previous
